Rexon-Eye Quantum Molecular Resonance Electrotherapy for Dry Eye Disease
Most device-based dry eye treatments target the lipid layer and the meibomian glands. Rexon-Eye is different: it applies electrical energy over the closed eye and is proposed to act on all the tissues involved in dry eye — meibomian glands, lacrimal tissue and the ocular surface — which positions it for mixed-type disease where both the aqueous and lipid layers are failing.
How Rexon-Eye works
Rexon-Eye (Resono Ophthalmic) delivers Quantum Molecular Resonance (QMR) — low-power, high-frequency electrical currents (in the megahertz range) applied through a mask-style electrode placed over the closed eyelids. The proposed mechanism is that these specific high-frequency, low-energy currents stimulate cellular activity and regeneration and reduce inflammation without generating significant heat, thereby improving meibomian gland and lacrimal function and stabilising the ocular surface. Because it does not depend on melting meibum alone, it is offered across aqueous-deficient, evaporative and mixed dry eye. The standard protocol is one 20-minute session per week for four weeks.
What the evidence shows
The most detailed published clinical data come from Trivli et al. (2023, Journal of Optometry), a prospective interventional study of 18 patients with medium-to-severe mixed-type dry eye treated with the standard four-session Rexon-Eye protocol and reassessed one month later. Both symptoms and multiple objective signs improved significantly:
| Outcome | Direction | Significance |
|---|---|---|
| OSDI symptom score | Improved | p = 0.013 |
| Non-invasive tear break-up time (NIBUT) | Improved | p < 0.001 |
| Oxford corneal staining | Improved | p = 0.002 |
| Expressible meibomian glands | Increased | p = 0.001 |
| Meibum quality | Improved | p < 0.001 |
| Ocular inflammation (MMP-9) | Reduced | p = 0.003 |
| Tear meniscus height; Schirmer's test | Slight / no change | Not significant |
A notable feature of this study was the significant fall in the inflammatory marker MMP-9 — a measurable readout of reduced ocular surface inflammation — alongside the tear-film and meibomian gland improvements. No adverse events were reported. The signals were strongest for tear stability, gland expressibility and inflammation, and weakest for the purely aqueous measures (tear meniscus height and Schirmer's test), which did not reach significance in this small cohort.
An honest read of the evidence
Rexon-Eye is an emerging therapy and the evidence should be read as such: the anchor study is a small, non-randomised prospective cohort, and larger randomised, sham-controlled trials are needed to confirm the effect size and define which dry eye subtypes benefit most. Its promise — a comfortable, heat-free treatment that appears to touch inflammation and both tear-film layers — is real, but it is a therapy to deploy on clinical judgement within a staged plan while the higher-level evidence matures.
Device-based dry eye research at NZERC
A novel modality with early but encouraging data is precisely where a research-capable centre earns its place — generating the randomised, controlled evidence the field is asking for. The New Zealand Eye Research Centre (NZERC) runs quantum molecular resonance and other device-based dry eye therapies within a structured, measurement-driven ocular surface service built for clinical research. Research organisations, device manufacturers and sponsors evaluating a New Zealand site for dry eye, MGD or ocular surface inflammation studies are invited to partner with NZERC. Clinicians and practices are welcome to contact Rose Optometry for support with complex ocular surface cases.
References
- Trivli A, Karmiris E, Dalianis G, Ruggeri A, Terzidou C. Evaluating the efficacy of Quantum Molecular Resonance (QMR) electrotherapy in mixed-type dry eye patients. Journal of Optometry. 2023. PMID 35851496.
- Jones L, Craig JP, Markoulli M, et al. TFOS DEWS III: Management and Therapy. American Journal of Ophthalmology. 2025;279:289-386.
.svg)
